TuHURA Biosciences Past Earnings Performance
Past criteria checks 0/6
TuHURA Biosciences has been growing earnings at an average annual rate of 20.4%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
20.4%
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How TuHURA Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -19 | 3 | 11 |
| 31 Dec 23 | 0 | -29 | 4 | 9 |
Quality Earnings: HURA is currently unprofitable.
Growing Profit Margin: HURA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if HURA's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare HURA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HURA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: HURA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.